Abstract: SA-PO453
Outcomes and Costs of Central Venous Catheter (CVC)-Related Staphylococcus aureus Bloodstream Infections (SA-BSI) in Hemodialysis (HD) Patients (Pts) With SA Nares Colonization (SA-NC) and Diabetes Mellitus (DM)
Session Information
- Hemodialysis and Frequent Dialysis: Clearance, Technology, Infection
November 05, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
Abstract Time: 10:00 AM - 12:00 PM
Category: Dialysis
- 701 Dialysis: Hemodialysis and Frequent Dialysis
Authors
- Patel, Nimish, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, San Diego, California, United States
- Dwyer, Jamie P., University of Utah Health, Salt Lake City, Utah, United States
- Berne, Lynda, BAL Pharma Consulting, Princeton, New Jersey, United States
- Young, Clarence L., Botanix Pharmaceuticals Limited, North Perth, Western Australia, Australia
- Callahan, Matthew, Botanix Pharmaceuticals Limited, North Perth, Western Australia, Australia
- Robinson, Anthony G., Botanix Pharmaceuticals Limited, North Perth, Western Australia, Australia
- Lodise, Thomas P., Albany College of Pharmacy and Health Sciences, Albany, New York, United States
Background
The rate of SA-BSIs in pts who start in-center HD with a CVC is estimated to be ~1 cases per 100-person months (PMID: 28663227), with higher rates observed in CVC-HD pts with SA-NC and DM. This study estimated the yearly outcomes and costs attributable to CVC-related SA-BSIs in adult CVC-HD pts with SA-NC and DM who start in-center HD.
Methods
A probabilistic model from the US Healthcare Perspective (1-year time horizon) was developed. The study population consisted of ~45,000 pts with DM as primary cause of ESRD who start in-center CVC-HD each year. Markov modeling (4 12-week cycles) was used to simulate the transitions between the different health-related dynamic states of CVC-HD pts with SA-NC and DM and estimate the yearly CVC-related SA-BSI-related outcomes and costs. Time on CVC, prevalence of SA-NC, CVC-related SA-BSI rates, CVC-related SA-BSI re-infection rates, 12-week SA-BSI costs (first episode and re-infections), and CVC-related SA-BSI death rates were identified in comprehensive literature review (Figure 1).
Results
Data indicate that 18,000 of the 45,000 annual incident CVC-HD pts with DM have SA-NC. Among CVC-HD pts with SA-NC and DM, the model estimates that there are 3,690 CVC-related SA-BSIs, 720 SA-BSI-related re-infections, and 900 SA-BSI-related deaths annually. Attributable yearly mean (SD) costs are projected to be 229 (51) million USD.
Conclusion
The estimated annual incidence of CVC-related SA-BSIs in CVC-HD pts with DM who start in-center HD that is attributable to SA-NC is high, resulting in considerable morbidity, mortality, and healthcare costs. New technologies are needed to prevent CVC-related SA-BSIs in this population.
Funding
- Commercial Support – Botanix